Policy
Biopharma Industry Alarmed by Prospect of RFK Jr. Shaping FDA Policies Under Trump Administration
RFK Jr., FDA, Trump Administration, Biopharma, Healthcare Policy, Agriculture Policy
Federal Agency Rejects J&J’s 340B Rebate Model, Vows to Take Action
340B Program, Johnson & Johnson, Rebate Model, Federal Agency Opposition, Healthcare Policy
Unlocking Direct-to-Consumer (DTC) Adoption: Leveraging Telehealth Programs for Enhanced Healthcare Access” ###
Direct-to-Consumer (DTC) digital health, Telehealth adoption, Virtual care platforms, Clinical networks, Consumer health and pharma leaders, Telemedicine services, Healthcare consumption, Primary care, Reimbursement models, Policy perspectives
Record-Breaking 323 Medications in Active Shortage in US, ASHP Reports
Drug shortages, US, Record-high, American Society of Health-System Pharmacists (ASHP), 323 medications, Active shortages, Generic sterile injectable medications, Cancer chemotherapy drugs, ADHD medications, Adderall, Drug Enforcement Administration (DEA), Drug supply chains, Policy recommendations